General AML

ASCO 2019 | Impact of genetic mutations in gilteritinib treated patients with FLT-3 mutated R/R AML


At the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, Mark J. Levis, Johns Hopkins University, Baltimore, US discussed an abstract based on the impact of co-mutations and FLT-3 allelic burden on the outcome of patients treated with gilteritinib in the randomized ADMIRAL study (NCT02421939). Dr. Levis explained that in this follow-up study, the FLT3 inhibitor, gilteritinib, showed superior response and overall survival (OS) compared with salvage chemotherapy (SC) in patients with FLT3mut+ R/R AML. Dr. Levis analyzed the impact of baseline co-mutations and FLT3-ITD allelic ratio (AR) on response and OS.